VAXART INC

Day range

$0.41 – $0.45

Open

$0.45

Prev close

$0.44

Volume

339.24K

Market cap

—

Shares out

—

P/E

—

P/S

1.24

P/B

3.05

P/FCF

—

ROE

-172.3%

ROA

-34.5%

Debt/Equity

0.09

Div yield

0.00%

As of Oct 22, 2026

• Exchange listingJul 8, 2025

  On July 8, 2025, Vaxart, Inc. (the "Company") issued a press release announcing that the Company's common stock has been approved to trade on the OTCQX® Best Market.

• Exchange listingJul 2, 2025

  on July 2, 2024, Vaxart, Inc. (the "Company") received a written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive business days, it no longer complied with the minimum bid price requirement (the "Minimum Bid Price Requirement") for continued listing under Nasdaq Listing Rule 5550(a)(2) on The Nasdaq Capital Market. The Company was provided until December 30, 2024, to regain compliance with the Minimum Bid Price Requirement.

• Business developmentsJun 11, 2025

  On June 11, 2025, Vaxart, Inc. (the "Company") issued a press release announcing topline clinical trial data from the Phase 1 clinical trial evaluating the Company's second-generation oral pill norovirus vaccine constructs head-to-head against its first-generation constructs.

• Governance documentsJun 2, 2025

  Proposal No. 2, which is the proposal to adopt and approve an amendment to the Company's Restated Certificate of Incorporation to allow the Company's Board of Directors, if they deem necessary, to effect a reverse stock split of issued shares of the Company's common stock into a lesser number of shares.

• Shareholder meetingsMay 22, 2025

  The reconvened Annual Meeting will be held on Monday, June 2, 2025 at 8:30 a.m. Pacific Time through live webcast of the meeting, as described on the Proxy Statement and proxy card or in the instructions that accompanied the proxy materials to the Company's stockholders.

Days to cover

4.7

Short interest

2.33M

Avg volume

499.84K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
  positiveGlobeNewswire Inc.· Jul 1, 2026
• Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
  positiveGlobeNewswire Inc.· Jun 26, 2026
• 3 Stocks Under $5 With Strong Analyst Upside Potential
  positiveInvesting.com· Feb 24, 2026
• Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
  positiveBenzinga· Nov 5, 2025
• Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
  positiveBenzinga· Nov 5, 2025